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CD155 on HIV-Infected Cells Is Not Modulated
by HIV-1 Vpu and Nef but Synergizes with NKG2D
Ligands to Trigger NK Cell Lysis of Autologous
Primary HIV-Infected Cells
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Abstract

Activation of primary CD4+ T cells induces the CD155, but not the CD112 ligands for the natural killer (NK) cell
activation receptor (aNKR) CD226 [DNAX accessory molecule-1 (DNAM-1)]. We hypothesize that HIV productively infects activated CD4+ T cells and makes itself vulnerable to NK cell-mediated lysis when CD155 on infected
T cells engages DNAM-1. The primary objective of this study is to determine whether CD155 alone or together with
NKG2D ligands triggers autologous NK cell lysis of HIV-infected T cells and whether HIV modulates CD155. To
determine whether HIV modulates this activation ligand, we infected ‘‘activated’’ CD4+ T cells with HIV in the
absence or presence of Nef and/or Vpu and determined by flow cytometry whether they modulated CD155. To
determine if CD155 alone, or together with NKG2D ligands, triggered NK cell lysis of autologous HIV-infected T
cells, we treated purified NK cells with DNAM-1 and/or NKG2D blocking antibodies before the addition of purified
autologous HIV-infected cells in cytolytic assays. Finally, we determined whether DNAM-1 works together with
NKG2D as an NK cell coactivation receptor (caNKR) or whether they work independently as aNKRs to induce an
NK cell lytic response. We demonstrate that HIV and specifically Nef and/or Vpu do not modulate CD155 on infected
primary T cells; and both CD155 and NKG2D ligands synergize as aNKRs to trigger NK cell lysis of the infected cell.
Keywords: natural killer cells, HIV, Nef, Vpu, cytotoxic
pathogen products (e.g., influenza hemagglutinin).7 Engagement of a single aNKR is insufficient to trigger a cytotoxic response by the NK cell. A coactivation receptor (caNKR)
must also be triggered simultaneously with an aNKR in order
for an NK cell to mediate its effector functions.11–13
In addition to expression of ligands to aNKRs and caNKRs
major histocompatibility complex class I (MHC-I) molecules
are another element that must be overcome for an NK cell to
effectively respond to a target cell. MHC-I molecules on
normal target cells trigger inhibitory receptors on NK cells
(iNKRs), thus preventing them from functioning even when
aNKRs are triggered simultaneously.14–17
We and other investigators demonstrated that ligands to
the NK cell aNKR NKG2D are induced by HIV-1 Vpr. Cell
surface expression of these ligands on HIV-infected T cells
trigger NK cells to lyse the infected cells.18,19

Introduction

N

atural killer (NK) cells function as innate ‘‘sentinels’’ of the immune system. These lymphocytes
circulate through the blood and lymph or reside within tissues in search of abnormal or virus-infected cells to rapidly
eliminate them before the development of systemic disease.
NK cells respond within minutes to hours following infection
or transformation of cells and do not require prior recognition
of components from abnormal or pathogen-infected cells.1–5
NK cells destroy infected and tumorigenic cells following
activation receptor (aNKR)-mediated recognition of molecules that are expressed on the infected or abnormal cell
surface.6–9 Activation ligands are induced to be expressed
as a result of activation (e.g., CD155/CD112),10 as a result of
‘‘cellular stress’’ (e.g., ULBPs),8 or expressed as cell surface
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In our previous studies, we demonstrated that even
though Nef downmodulates HLA-A and -B,20 and Vpr induces NKG2D activation ligands,18 HIV-1 avoids lysis by
NK cells by downmodulating NTB-A through Vpu.21 We
showed that a mutated Vpu, which could not downmodulate
NTB-A, greatly enhanced NK cell lysis of the infected
T cells.21 The lysis of T cells infected with a virus containing the mutated Vpu was reversed in the presence of
blocking antibodies to NTB-A.21 These findings indicate
that HIV-1 Vpu primarily affects NTB-A and not other NK
cell activation ligands.
However, it remains to be determined if other NK cell
aNKR ligands trigger NK cells to lyse the HIV-infected
cells. We did not observe the presence of ligands to NCRs
NKp30, NKp44, and NKp46 on primary HIV-infected
T cells.22 Recently, CD155 was shown to be present on
HIV-infected T cells and could be a potential ligand that
triggers NK cell lysis of the infected cell.23 This study also
reported that the HIV-1 viral proteins Nef and Vpu antagonize cell surface expression of CD155 and allow HIV to
evade NK cell lysis.23 A subsequent study reported that Vpu
downmodulates CD155 through its transmembrane residues’ (A10xxxA14xxxA18xxxW22) interaction with CD155
and sequesters it within the cell, thereby preventing its
presentation on the cell surface.24
The discrepancy between our previous studies21 and those
by other investigators23 may lie in the differences of HIV-1infected target cells used. We used purified HIV-infected T
cells as target cells in our cytotoxic assays,25 while the studies
by Matusali et al.23 utilized HIV-infected Jurkat T-cell lines
as target cells in their lytic assay. HIV-infected Jurkat cells
may express different types and levels of NK cell activation
ligands not seen with primary CD4+ T cells. Therefore, we
wanted to determine whether Vpu and/or Nef modulated
CD155 on the natural host cell of HIV, primary CD4+ T-cell
blasts, to avoid lysis by autologous NK cells.
In this study, we demonstrate that (1) activated primary
CD4+ T cells express CD155; (2) HIV and specifically Nef
and/or Vpu do not modulate CD155 on infected primary T
cells; and (3) CD155 and NKG2D ligands trigger NK cell
lysis of the infected cell, but this response appears optimal
when the caNKR NTB-A is triggered simultaneously.
Therefore, despite the presence of NK cell activation ligands,
CD155 and ULBP-1/-2, on HIV-infected cells, downmodulation of NTB-A by Vpu has consequences in the ability
of NK cells to lyse HIV-infected T cells.
Materials and Methods
Primary cells and cell lines

All primary cells (i.e., NK cells and CD4+ T cells) used in
this study were isolated from peripheral blood of healthy HIV1-uninfected donors after informed written consent was acquired in accordance with the Declaration of Helsinki and the
policies of the Institutional Review Board at Rush University
Medical Center, Chicago, IL. NK cells and CD4+ T cells were
isolated from the peripheral blood in separate blood draws and
stimulated in vitro as described in Ref.25 The P815 mouse
lymphoblast-like mastocytoma cell line (ATCC) was maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% heat-inactivated (56C, 30 min) fetal bovine serum
(FBS) and penicillin/streptomycin (Mediatech).

DAVIS ET AL.
HIV infection of primary CD4+ T cells

Freshly isolated primary CD4+ T cells were activated using
anti-CD3/anti-CD28 mAb coupled to magnetic beads (Miltenyi Biotech) for 72 h before infection with an HIV-1NL4-3 strain
in which HIV-1 envelope is deleted (DHIV3). We also infected
CD4+ T cells with the same strain of virus, which lacked Vpu,
Nef, or Nef and Vpu. These envelope-defective viruses were
VSV-G pseudotyped. A replication-incompetent virus was
used since Vpu and Nef could impact the replication capacity of
HIV-1 within CD4+ T cells. Infection was performed by spin
inoculation with a MOI50 = 1 as described in Ref.26 Following
the infection, the cells were cultured in the RPMI complete
medium with 200 U/ml recombinant IL-2 (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH,
deposited by Dr. Maurice Gately; Hoffmann-La Roche, Inc.).
Flow cytometry reagents and antibodies

Uninfected and infected T cells were first incubated with the
viability dye AquaDead LIVE/DEAD (Life Technologies)
before being surface stained with fluorochrome-conjugated
anti-CD155 [Biolegend (clone SKII.4)], anti-CD112 [Biolegend (clone TX31)], anti-NTB-A [Biolegend (clone 292811)],
anti-HLA-DR [Biolegend (clone L423)], anti-HLA-A, -B,
and -C [Biolgend (clone W6/32)], or anti-CD4 [BDIS (clone
RPA-T4)]. Cells were subsequently permeabilized and fixed
using Perm/Fix (BD Biosciences) and intracellularly stained
for HIV-1 p24 with fluorochrome-conjugated anti-HIV-1 Gag
p24 antibodies [Beckman-Coulter (clone KC57)]. HIV-1 p24
negative (p24-) and HIV-1 p24 positive (p24+) were collected
(2 · 105) on FACSLSRII (BD Biosciences) and analyzed using
FlowJo software (TreeStar). FACSLSRII was a generous gift
from the James B. Pendelton Charitable Trust.
Relative NTB-A and CD155 surface expression were
calculated as follows: [median fluorescent intensity (MFI) of
NTB-A or CD155 on p24+ cells-MFI of isotype of p24+
cells]/(MFI NTB-A or CD155 on p24- cells-MFI of isotype
of p24- cell) · 100. NTB-A and CD155 on uninfected cells
were set at 100%. In some studies we evaluated DNAM-1
[Biolegend (clone: 11AE)] expression of NK cell marker
(CD56+ CD3- CD14- CD19-) (vendor and clones of antibodies to CD56, CD3, CD14, and CD19 were similar to those
used in our previous study21).
CD107a degranulation and chromium release assays

NK cells were obtained from PBMCs of same donor as the
CD4+ T cells. NK cells were obtained from separate blood
drawn and was done 6–9 days after isolating CD4+ T cells
because it takes 7–10 days to stimulate and infect CD4+ T
cells with HIV-1. One day before the degranulation and cytotoxic assays, fresh NK cells were isolated from PBMC
using immunomagnetic beads (Miltenyi). After isolation, NK
cells were cultured overnight in either a plain medium or in a
medium containing 200 U/ml IL-2. The resulting purified and
cultured NK cells were placed in RPMI-1640 and 10% FBS
and exposed to target cells.
HIV-infected cells were isolated from uninfected cells in
bulk culture before addition to NK cells as described.25
Briefly, HIV-infected cells were treated with anti-CD4 Ab
coupled to magnetic beads (Invitrogen) at a ratio of 10 beads
per cell. The cells were incubated at 4C for 1 h. The cells
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FIG. 1. DNAM-1 ligand CD155, but not CD112, is expressed on activated CD4+ T cell and is not modulated by Nef or Vpu
during HIV infection. (A) Expression of CD155 (blue line), but not CD112 (blue line), on anti-CD3 and -CD28 antibody-treated
primary CD4+ T cells. Isotype controls (green line) for the CD155 and CD112 Ab are provided. This is an example of two
experiments. (B) Untreated and anti-CD3 and anti-CD28 antibody-treated primary CD4+ T cells were stained with anti-CD155
and anti-HLA-DR. Numbers in quadrant one and two represent the frequency of CD4+ T cells that stained with anti-CD155 or
anti-CD155 and anti-HLA-DR. This is an example of two experiments. (C) Anti-CD3 and -CD28 antibody-treated primary
CD4+ T cells were infected with VSV-G-pseudotyped DHIV3 (WT), DHIV3 lacking Vpu (DVpu), DHIV3 lacking Nef (DNef),
or DHIV3 lacking both Vpu and Nef (DVpu DNef) for 3 days and then surface stained for CD155 or NTB-A. The cells were
then permeabilized and stained intracellularly for anti-HIV-1 p24 (red line). As a control, uninfected Anti-CD3 and -CD28
antibody-treated primary CD4+ T cells were evaluated (blue line). Isotype controls for both infected (orange line) and uninfected cells (green line) are provided. This is an example of five different subjects. (D) The mean relative surface expression of
CD155 or NTB-A –SD of five different subjects. Formula to determine relative levels of CD155 and NTB-A is provided in
Material and Methods section. The statistical significance of the relative CD155 of NTB-A surface expression was determined
using the Mann–Whitney U-test. p > .05 was not statistically significant. (E) HLA-A-A, -B, and -C expression on anti-CD3 and
-CD28 antibody-treated primary-uninfected CD4+ T cells (blue line) or anti-CD3 and -CD28 antibody-treated primary CD4+ T
cells infected (red line) with VSV-G-pseudotyped DHIV3 WT, with VSV-G pseudotyped DHIV3 lacking Vpu (DVpu), and
with VSV-G-pseudotyped DHIV3 lacking Nef (DNef). Isotype control antibody-stained cells are also provided (green line).
DNAM-1, DNAX accessory molecule-1; SD, standard deviation; WT, wild type.
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bound to the beads were removed with a magnet and the remaining cells suspension treated with another round of antiCD4 Ab coupled to magnetic beads for 1 h at 4C at a bead to
cell ratio of 10:1. The resulting cells, after immunomagnetic
bead separations of CD4+ T cells, were shown to be infected by
HIV as demonstrated by the presence of HIV-1 p24 antigen
within the unbound cells, which was determined as described.25
NK cell cytotoxic effector functions (both CD107a Degranulation and Chromium Release Assays) following exposure to target cells were evaluated as previously described
in extensive detail.25 Before the coculture of target cells with
NK cells, the NK cells were treated at 4C for 30 min with
10 lg/ml of the following antibodies: anti-human DNAM-1
antibody [R&D Systems (clone:102511) or BDIS (clone:
DX11)] and/or anti-human NKG2D antibody [R&D Systems
(clone:149810) or BDIS (clone: 1D11)].
In addition, we determined the extent to which purified NK
cells degranulated (surface CD107a expression) in response to
antibodies directed to CD16 [BDIS (clone: 3G8)], DNAM-1
[BDIS (clone: DX11)], NTB-A [R&D Systems (clone:292811)],
NKG2D [BDIS (clone:1D11)] or a combination of the antibodies. After treatment of P815 cells with antibodies for 30 min
at 4C, the NK cells were added to the culture. NK cells were
cocultured with antibody-labeled P815 cells for 4 h. As a control, we cocultured NK cells with P815 cells without antibody.
NK cells with target cells were labeled with fluorochromeconjugated anti-CD107a Ab [BDIS (clone H4A3) along with
CD56, CD3, CD14, and CD19 (all BDIS antibodies)]. NK
cells (CD56+ CD3- CD14- CD19- cells) were collected
(2 · 105) on FACSLSRII (BD Biosciences) and analyzed
using FlowJo software (TreeStar).
Statistical analyses

Nonparametric statistical analysis of the data in the study
was done using Mann–Whitney U-test to determine statistical
significance between two groups. p values £.05 were considered statistically significant.

DAVIS ET AL.
Results and Discussion
Activated primary CD4+ T cells express
the DNAM-1 ligand CD155, but not CD112,
and surface levels of CD155
is not modulated by HIV-1 Nef and/or Vpu

When evaluating the expression of the DNAM-1 ligands
CD155 (i.e., polio virus receptor) and CD112 (i.e., Nectin-2),
we found that only CD155 was expressed on anti-CD3 and
CD28 mAb-stimulated primary CD4+ T cells (Fig. 1A).
CD155 was present mostly (*80%) on ‘‘activated’’ CD4+ T
cells as indicated by coexpression of HLA-DR (Fig. 1B).
Infection of primary anti-CD3 and -CD28 Ab-stimulated
CD4+ T cells with HIV did not downmodulate CD155 even
though it significantly downmodulated NTB-A from the cell
surface (Fig. 1C). Moreover, there was no statistically significant increase in CD155 surface levels when HIV-1 Vpu
and/or Nef were removed from the virus (Fig. 1C, D). In
contrast, loss of Vpu greatly affected NTB-A surface expression [( p < .05); Fig. 1C, D] and loss of Nef from HIV led
to the increased expression of MHC-I (Fig. 1E). Thus, it
appears that the activation of CD4+ T cells induces CD155 on
the cell surface and HIV-1 infection of CD4+ T cells does not
significantly impact CD155 surface expression, but does result in the decrease of both MHC-I and NTB-A expression on
the infected cell surface.
Since HIV-1-infected CD4+ primary T cells express
CD155, we next wanted to determine if the presence of
CD155 contributed to NK cell lysis of infected CD4+ T cells.
To test this, we utilized a blocking antibody against DNAM-1
on NK cells to impair its interaction with CD155 on autologous HIV-infected cells and then compared the contribution
of DNAM-1 to NK cell lysis of autologous HIV-infected CD4+
T cells with that of NKG2D. We18 and other investigators19
have previously demonstrated that HIV-1 Vpr induces NKG2D
ligands (i.e., ULBP-1 and -2) on primary HIV-infected T cells.
As a control, we also evaluated the ability of NK cells to lyse
uninfected CD4+ T cells.

‰
FIG. 2. NK cells lyse autologous HIV-infected T cells when DNAM-1 and NKG2D are triggered by HIV-infected T cells.
+
(A, B) anti-CD3 and -CD28 antibody-treated primary CD4 T cells were infected with VSV-G-pseudotyped DHIV3 for
3 days. The infected cells were then separated from the uninfected cells using anti-CD4 beads. The unattached cells that
remained behind were used as target cells. As a control target cell, we utilized anti-CD3 and -CD28 antibody-treated
primary CD4+ T cells (white bar). Target cells were labeled with 51Cr for 2 h and then mixed with NK cells at effector cell
to target cell (E:T) ratios of 2.5:1, 5:1, or 10:1. In some groups, NK cells were incubated with blocking antibodies to
DNAM-1 (hashed line bar), NKG2D (gray bar), DNAM-1, and NKG2D (horizontal line bar) or control antibody of similar
isotype as blocking antibody (black bar). After 4 h, fluids were removed and the remaining 51Cr in the fluid was measured.
Each group was done in triplicate. The mean % specific lysis –SD was determined as described in Material and Methods
section. Each Figure (A, B) represents data from experiments involving two separate donors. (C) Purified NK cells cultured
in a medium or 200 U/ml of IL-2 were stained with CD56 and DNAM-1. (D) Similar to A and B except NK cells were
treated overnight with 200 U/ml of IL-2 before their use in the 51Cr release assay and involved a different donor. (E) Ability
of NK cells to degranulate when exposed to autologous HIV-infected T cells (NK cell:HIV-infected cell ratio of 2:1) when
exposed to anti-DNAM-1, anti-NKG2D, or a combination of both blocking antibody when compared with NK cells exposed
to Ig of irrelevant specificity. Each symbol represents a different donor. Bars represent mean percent decrease in frequency
of CD107a+ NK cells in the presence of blocking antibody to DNAM-1 and/or NKG2D compared to frequency of CD107a+
NK cells treated with antibody of irrelevant specificity. The statistical difference between treatment groups was determined
using the Mann–Whitney U-test. (F) Degranulation of NK cells from a donor involved in the study presented in (E)
following exposure to target cells in the presence of control of blocking antibodies. NK cell degranulation following
exposure to control target cells (i.e., uninfected CD4+ T cells and K562 cells) is displayed. (G) Degranulation of NK cells
when triggered with antibodies to DNAM-1, NTB-A, NKG2D, or a combination of the various antibodies. Antibody-labeled
P815 cells were treated with NK cells for 4 h and the extent to which the NK cells degranulated was measured by
determining the frequency of NK cells that expressed CD107a on their surface. Each figure represents data from experiments involving three separate donors. NK, natural killer.
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As shown in Figure 2A and B, NK cells from two different
donors were able to lyse HIV-infected cells 15–25-fold higher
in the presence of a control antibody in comparison to NK cell
lysis of uninfected target cells. As expected, blocking NKG2D
on NK cells led to a decrease in their ability to lyse autologous
HIV-infected cells (Fig. 2A, B). In contrast, blocking DNAM1 led to a modest decrease in the lysis of HIV-infected cells
(Fig. 2A, B). However, when both DNAM-1 and NKG2D are
prevented from interacting with their ligands on the infected
cell surface, the ability to lyse HIV-infected T cells dropped
close to or at levels observed with NK cell lysis of uninfected
cells. Thus, it appears that CD155 and ULBP-1/-2 work in
concert with one another to trigger optimal primary NK cell
lysis of autologous HIV-infected cells.
Next, we wanted to determine what affect stimulation of
NK cells with IL-2 would have on the ability of NK cells to
lyse HIV-infected T cells in the presence or absence of
DNAM-1 signaling. This is important given that, on IL-2treated NK cells, cis-binding of DNAM-1 to LFA-1 leads to
intracellular signaling.27 We noted no change to the frequency
of NK cells expressing DNAM-1 before and after stimulation
with IL-2 (Fig. 2C). We noted that the level of NK cell-mediated
lysis of HIV-infected cells was similar whether it used
DNAM-1 or NKG2D to trigger lysis (Fig. 2D). However,
the combination of triggering both receptors gave the best
lytic response as indicated by our study, where we found
that blocking the interaction of DNAM-1 and NKG2D on
NK cells with its ligands on the infected cells led to a level
of lysis comparable to NK cell lysis to uninfected T cells.
Using another assay (degranulation assay) to evaluate the
role of DNAM-1 on NK cell cytotoxic response to HIVinfected cells, we demonstrate that blocking DNAM-1 had
only a marginal impact on the ability of NK cells to degranulate in response to autologous HIV-infected cells in
comparison to blocking NKG2D ( p = .07) (Fig. 2E, F).
However, when blocking DNAM-1 is paired with blocking
NKG2D, NK cell degranulation occurred to a lesser degree
compared with blocking either receptor alone ( p = .001 antiDNAM-1 vs. anti-NKG2D and anti-DNAM-1 and p = .003
anti-NKG2D vs. anti-NKG2D and anti-DNAM-1).
Although both DNAM-1 and NKG2D are important for
lysis of HIV-infected cells, it remains to be determined if they
work independently or act as coreceptors. To determine if
DNAM-1 and NKG2D require each other for cell lysis or are
just separate aNKRs that work independent of one another,
we utilized a redirected lysis assay where we triggered
NKG2D and DNAM-1 on NK cells using anti-NKG2D or
anti-DNAM-1 antibodies as ligand mimics, either alone or
combined, in the presence of P815 cells (to crosslink the Ig
molecules bound to the receptors). By doing so, we were able
to determine if NKG2D and DNAM-1 act independent of one
another, using another caNKR (e.g., NTB-A) or are caNKRs
for one another. As a positive control for this study for
coactivation of NK cells leading to degranulation, we triggered NKG2D with NTB-A with specific antibodies.21
Although, it is ideal to use primary cells as targets for this
study, there are too many possible combinations of ligands
(both ligands to aNKRs and caNKRs) on HIV-infected primary cells to decipher the specific role of NKG2D and
DNAM-1 in eliciting the cytolytic response. Moreover, additional ligands on HIV-infected cells involved in eliciting
NK cell cytolysis remain to be determined.

DAVIS ET AL.

As predicted,21 triggering NKG2D and NTB-A leads to
NK cell degranulation (Fig. 2G). In addition to NK cell
degranulation occurring when NKG2D and NTB-A are
engaged at the same time, triggering DNAM-1 and NTB-A
simultaneously leads to NK cell degranulation above the
additive levels of degranulation when either were triggered
alone (Fig. 2G). Based on the data presented in our study, it
appears that DNAM-1 and NKG2D act independent of one
another as aNKRs for NK cell killing of HIV-infected cells,
instead requiring another caNKR such as NTB-A in order
for NK cells to degranulate (Fig. 2G). Thus, downmodulation of NTB-A by Vpu (Fig. 1C, D) would most
likely dampen the maximal capacity of NK cells to kill HIVinfected cells even when both NKG2D and DNAM-1 were
triggered on NK cells.21
One explanation for the discrepant results between the
previous studies23 and this investigation may be the fact that
we used only purified infected primary CD4+ T cells, whereas
the previous studies were done using infected Jurkat cell lines
as target cells in their lytic assay. In addition to this, we
utilized MFI of anti-CD155 staining for primary infected
cells and their mutants since the histograms do not follow a
normal, but rather skewed, binomial distribution (Fig. 1C).
While we did see a statistically significant difference in the
ability of Vpu to modulate NTB-A, we found no statistical
difference in the ability of HIV to modulate CD155 through
Vpu and/or Nef.
It is of interest that activated uninfected CD4+ T cells
express CD155 and yet are not lysed to the same extent as
HIV-infected cells. This is likely due to expression of MHC-I
molecules, which trigger inhibitory receptors on NK cells to
prevent lysis. Although HIV downmodulates HLA-A and -B
on primary CD4+ T cells, HLA-C remains on the infected cell
surface. HLA-E is also present on the infected cell surface
and triggers inhibitory receptors expressed on NK cells.
However, we noted that HLA-E on HIV-infected cells is
unable to inhibit NK cell lysis.28 Thus, while NK cells have
the capacity to kill HIV-infected cells when triggered by
CD155, HIV-1s downmodulation of NTB-A dampens the
synergistic signal critical for DNAM-1-induced NK cell degranulation.
Although our study focuses on the role of CD155 on
triggering the activation of NK cells through DNAM-1, there
is a need to determine the role that CD155 will have on
triggering the inhibitory receptor, T cell, immunoglobulin,
and intracellular tyrosine inhibitory motifs (TIGIT) on NK
cells.29,30 TIGIT is an immune cell-specific immunoglobulin
superfamily receptor of the CD28 family, which is present on
the cell surface of 20%–90% of human NK cells with a
median of 64%.31 Similar to DNAM-1, TIGIT binds to
CD112 and CD155; however, TIGIT affinity for CD112 and
CD155 is higher compared with DNAM-1.32 Moreover, TIGIT is often coexpressed with DNAM-1 on NK cells,31
making it likely that inhibition of NK cell function will
dominate over activation when the NK cells encounter a
target cell expressing CD155.
Although TIGIT prevents NK cells from lysing normal
primary fibroblasts,29 it has not been determined if TIGIT
modulates NK cell responses against autologous HIV-infected
cells. The primary focus in studies evaluating the role of
inhibitory receptor on NK cell response to HIV-infected cells
is on iNKR responses to MHC class I molecules.20,28,33–36

CD155 AND ULBP TRIGGER NK CELL RESPONSE TO HIV

Since some KIRs may not be engaged due to modulation of
HLA-A and -B by Nef33,37 or the inability of HLA-E to
trigger the iNKR NKG2A/CD9428 and as we show in this
study, HIV does not modulate CD155 on CD4+ T cells, it is
likely that TIGIT may contribute to modulating NK cell response to HIV-infected cells.
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